221 related articles for article (PubMed ID: 10483476)
1. Treatment of experimental burn wound sepsis by postburn immunization with polyvalent Pseudomonas antigen.
Nance FC; Hines JL; Fulton RE; Bornside GH
Surgery; 1970 Jul; 68(1):248-53. PubMed ID: 10483476
[TBL] [Abstract][Full Text] [Related]
2. [Results of using polyvalent Pseudomonas aeruginosa vaccine in children with burns by various medical centers].
Bbukowska D; Serafińska D; Rudowski W; Hoffman S; Olański W; Gardzińska E; Popiel D; Jedrzejczak G; Czarnecka I
Pol Tyg Lek; 1989 Oct 23-Nov 6; 44(43-45):924-7. PubMed ID: 2518666
[TBL] [Abstract][Full Text] [Related]
3. Investigations on the efficacy of monovalent Pseudomonas aeruginosa vaccine for oral administration in Pseudomonas aeruginosa experimental infection.
Meitert E; Sima F; Savulian C; Petrovici M; Chersulick E; Costache G
Arch Roum Pathol Exp Microbiol; 1989; 48(3):237-51. PubMed ID: 2519634
[TBL] [Abstract][Full Text] [Related]
4. Protective efficacy of Pseudomonas aeruginosa type-A flagellin in the murine burn wound model of infection.
Faezi S; Safarloo M; Amirmozafari N; Nikokar I; Siadat SD; Holder IA; Mahdavi M
APMIS; 2014 Feb; 122(2):115-27. PubMed ID: 23758581
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the immune responses following co-administration of PilQ and type b-flagellin from Pseudomonas aeruginosa in the burn mouse model.
Bakht Azad S; Nikokar I; Faezi S; Rasooly S; Mahdavi M
Microb Pathog; 2018 Oct; 123():426-432. PubMed ID: 30075242
[TBL] [Abstract][Full Text] [Related]
6. [Our experience with the treatment of burns with sheep serum against Pseudomonas aeruginosa].
Orłowski T; Struzyna J; Badowski A; Schiller B; Kuntze A; Kozaczek W; Goller W
Wiad Lek; 1980 Nov; 33(21):1697-701. PubMed ID: 6784349
[No Abstract] [Full Text] [Related]
7. Therapy with anti-flagellin A monoclonal antibody limits Pseudomonas aeruginosa invasiveness in a mouse burn wound sepsis model.
Barnea Y; Carmeli Y; Neville LF; Kahel-Reifer H; Eren R; Dagan S; Navon-Venezia S
Burns; 2009 May; 35(3):390-6. PubMed ID: 18951715
[TBL] [Abstract][Full Text] [Related]
8. Prevention and treatment of sepsis in burns.
Lowbury EJ
Proc R Soc Med; 1972 Jan; 65(1):25-7. PubMed ID: 4335587
[No Abstract] [Full Text] [Related]
9. Effects of somatic component of Pseudomonas aeruginosa on protective immunity in experimental mouse burn infection.
Okada K; Kawaharajo K; Kasai T; Homma JY
Jpn J Exp Med; 1980 Feb; 50(1):53-61. PubMed ID: 6770131
[TBL] [Abstract][Full Text] [Related]
10. Glucan phosphate treatment attenuates burn-induced inflammation and improves resistance to Pseudomonas aeruginosa burn wound infection.
Lyuksutova OI; Murphey ED; Toliver-Kinsky TE; Lin CY; Cui W; Williams DL; Sherwood ER
Shock; 2005 Mar; 23(3):224-32. PubMed ID: 15718919
[TBL] [Abstract][Full Text] [Related]
11. [Pseudomonas aeruginosa preparations for active immunization].
Nazarchuk LV
Vrach Delo; 1991 Jul; (7):22-7. PubMed ID: 1771827
[No Abstract] [Full Text] [Related]
12. Motility, virulence, and protection with a flagella vaccine against Pseudomonas aeruginosa infection.
Montie TC; Drake D; Sellin H; Slater O; Edmonds S
Antibiot Chemother (1971); 1987; 39():233-48. PubMed ID: 3118785
[No Abstract] [Full Text] [Related]
13. [[Vaccine development for P. aeruginosa: based on antigen cloning of clinical vaccines][].
von Specht BU
Zentralbl Chir; 1999; 124(4):298-302. PubMed ID: 10355084
[TBL] [Abstract][Full Text] [Related]
14. [Results of using a polyvalent vaccine against Pseudomonas aeruginosa in patients with burns treated at various therapeutic centers in Poland].
Bukowska D; Serafińska D; Zietkiewicz W; Rudowski W; Hoffman S; Uszyński H; Molski M; Hess C; Jonecko A; Popiel D
Pol Tyg Lek; 1986 Dec; 41(49):1549-52. PubMed ID: 3108869
[No Abstract] [Full Text] [Related]
15. [Morphological study of the organs and tissues of mice infected after a burn with a Pseudomonas aeruginosa strain and treated with a Pseudomonas aeruginosa polyvalent corpuscular vaccine and tobramycin].
Moroz AF; Kharitonova AM; Chanturiia TsK
Antibiotiki; 1983 May; 28(5):341-5. PubMed ID: 6410985
[TBL] [Abstract][Full Text] [Related]
16. [Use of a vaccine for prevention of Pseudomonas aeruginosa infection of burn wounds in mice].
Grochowski J; Bilinska M; Stankiewicz D; Arkusiewicz E
Pol Przegl Chir; 1979 Jun; 51(6):623-7. PubMed ID: 116210
[No Abstract] [Full Text] [Related]
17. [Immunogenic properties and specificity of pseudomonas aeruginosa polyvalent vaccine].
Schiller B; Lysakowska E; Owczarska K
Med Dosw Mikrobiol; 1981; 33(2):91-6. PubMed ID: 6170849
[No Abstract] [Full Text] [Related]
18. [Effectiveness of tobramycin and immunologic preparations in experimental Pseudomonas infection].
Minukhin VV; Tsyganenko AIa
Antibiot Khimioter; 1989 Apr; 34(4):282-6. PubMed ID: 2502083
[TBL] [Abstract][Full Text] [Related]
19. Application of vaccine technology to prevention of Pseudomonas aeruginosa infections.
Pier G
Expert Rev Vaccines; 2005 Oct; 4(5):645-56. PubMed ID: 16221066
[TBL] [Abstract][Full Text] [Related]
20. [Serum IgG concentrations and antibody titer of burn patients after preventive intravenous IgG substitution with a Pseudomonas immunoglobulin].
Stuttmann R; Hartert M; Jahn M; Spilker G; Doehn M
Infusionsther Transfusionsmed; 1993 Apr; 20 Suppl 1():48-55. PubMed ID: 8499751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
